Francisco Miguel Cruz

Francisco Miguel Cruz

Auto-generated profile, based on publicly available information

Francisco Miguel Cruz

Centro Nacional de Investigaciones Cardiovasculares (CNIC) Carlos III, Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV)

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 June 2022 in eLife
Verified
Journal Article
Open access
EJEric Nahum Jimenez-Vazquez
Eric Nahum Jimenez-Vazquez
MAMichael Arad
Michael Arad
Álvaro MacíasÁlvaro Macías
Álvaro Macías
MVMaria L Vera-Pedrosa
Maria L Vera-Pedrosa
FCFrancisco Miguel Cruz
Francisco Miguel Cruz
Jose JalifeJose Jalife
Jose Jalife
Background: Patients with cardiomyopathy of Duchenne Muscular Dystrophy (DMD) are at risk of developing life-threatening arrhythmias, but the mechanisms are unknown. We aimed to determine the role of ion channels controlling cardiac excitability in the mechanisms of arrhythmias in DMD patients.Methods: To test whether dystrophin mutations lead to defective cardiac NaV1.5–Kir2.1 channelosomes and arrhythmias, we generated iPSC-CMs from two hemizygous DMD males, a heterozygous female, and two unrelated control males. We conducted studies including confocal microscopy, protein expression analysis, patch-clamping, non-viral piggy-bac gene expression, optical mapping and contractility assays.Results: Two patients had abnormal ECGs with frequent runs of ventricular tachycardia. iPSC-CMs from all DMD patients showed abnormal action potential profiles, slowed conduction velocities, and reduced sodium (INa) and inward rectifier potassium (IK1) currents. Membrane NaV1.5 and Kir2.1 protein levels were reduced in hemizygous DMD iPSC-CMs but not in heterozygous iPSC-CMs. Remarkably, transfecting just one component of the dystrophin protein complex (α1-syntrophin) in hemizygous iPSC-CMs from one patient restored channelosome function, INa and IK1 densities, and action potential profile in single cells. In addition, α1-syntrophin expression restored impulse conduction and contractility and prevented reentrant arrhythmias in hiPSC-CM monolayers.Conclusions: We provide the first demonstration that iPSC-CMs reprogrammed from skin fibroblasts of DMD patients with cardiomyopathy have a dysfunction of the NaV1.5–Kir2.1 channelosome, with consequent reduction of cardiac excitability and conduction. Altogether, iPSC-CMs from patients with DMD cardiomyopathy have a NaV1.5–Kir2.1 channelosome dysfunction, which can be rescued by the scaffolding protein α1-syntrophin to restore excitability and prevent arrhythmias.Funding: Supported by National Institutes of Health R01 HL122352 grant; ‘la Caixa’ Banking Foundation (HR18-00304); Fundación La Marató TV3: Ayudas a la investigación en enfermedades raras 2020 (LA MARATO-2020); Instituto de Salud Carlos III/FEDER/FSE; Horizon 2020 - Research and Innovation Framework Programme GA-965286 to JJ; the CNIC is supported by the Instituto de Salud Carlos III (ISCIII), the Ministerio de Ciencia e Innovación (MCIN) and the Pro CNIC Foundation), and is a Severo Ochoa Center of Excellence (grant CEX2020-001041-S funded by MICIN/AEI/10.13039/501100011033). American Heart Association postdoctoral fellowship 19POST34380706s to JVEN. Israel Science Foundation to OB and MA [824/19]. Rappaport grant [01012020RI]; and Niedersachsen Foundation [ZN3452] to OB; US-Israel Binational Science Foundation (BSF) to OB and TH [2019039]; Dr. Bernard Lublin Donation to OB; and The Duchenne Parent Project Netherlands (DPPNL 2029771) to OB. National Institutes of Health R01 AR068428 to DM and US-Israel Binational Science Foundation Grant [2013032] to DM and OB.

23 January 2024 in Cardiovascular Research
Verified
Journal Article
Open access
PDF file
AMAna I Moreno-Manuel
Ana I Moreno-Manuel
Álvaro MacíasÁlvaro Macías
Álvaro Macías
FCFrancisco M Cruz
Francisco M Cruz
LGLilian K Gutiérrez
Lilian K Gutiérrez
FMFernando Martínez
Fernando Martínez
Jose JalifeJose Jalife
Jose Jalife
Short QT syndrome type 3 (SQTS3) is a rare arrhythmogenic disease caused by gain-of-function mutations in KCNJ2, the gene coding the inward rectifier potassium channel Kir2.1. We used a multidisciplinary approach and investigated arrhythmogenic mechanisms in an in-vivo model of de-novo mutation Kir2.1E299V identified in a patient presenting an extremely abbreviated QT interval and paroxysmal atrial fibrillation. We used intravenous adeno-associated virus-mediated gene transfer to generate mouse models, and confirmed cardiac-specific expression of Kir2.1WT or Kir2.1E299V. On ECG, the Kir2.1E299V mouse recapitulated the QT interval shortening and the atrial-specific arrhythmia of the patient. The PR interval was also significantly shorter in Kir2.1E299V mice. Patch-clamping showed extremely abbreviated action potentials in both atrial and ventricular Kir2.1E299V cardiomyocytes due to a lack of inward-going rectification and increased IK1 at voltages positive to −80 mV. Relative to Kir2.1WT, atrial Kir2.1E299V cardiomyocytes had a significantly reduced slope conductance at voltages negative to −80 mV. After confirming a higher proportion of heterotetrameric Kir2.x channels containing Kir2.2 subunits in the atria, in-silico 3D simulations predicted an atrial-specific impairment of polyamine block and reduced pore diameter in the Kir2.1E299V-Kir2.2WT channel. In ventricular cardiomyocytes, the mutation increased excitability by shifting INa activation and inactivation in the hyperpolarizing direction, which protected the ventricle against arrhythmia. Moreover, Purkinje myocytes from Kir2.1E299V mice manifested substantially higher INa density than Kir2.1WT, explaining the abbreviation in the PR interval. The first in-vivo mouse model of cardiac-specific SQTS3 recapitulates the electrophysiological phenotype of a patient with the Kir2.1E299V mutation. Kir2.1E299V eliminates rectification in both cardiac chambers but protects against ventricular arrhythmias by increasing excitability in both Purkinje-fiber network and ventricles. Consequently, the predominant arrhythmias are supraventricular likely due to the lack of inward rectification and atrial-specific reduced pore diameter of the Kir2.1E299V-Kir2.2WT heterotetramer.

18 March 2024 in Circulation Research
Verified
Journal Article
Closed access
FCFrancisco M. Cruz
Francisco M. Cruz
Álvaro MacíasÁlvaro Macías
Álvaro Macías
AMAna I. Moreno-Manuel
Ana I. Moreno-Manuel
LGLilian K. Gutiérrez
Lilian K. Gutiérrez
MVMaría Linarejos Vera-Pedrosa
María Linarejos Vera-Pedrosa
Jose JalifeJose Jalife
Jose Jalife
BACKGROUND: Andersen-Tawil syndrome type 1 is a rare heritable disease caused by mutations in the gene coding the strong inwardly rectifying K+ channel Kir2.1. The extracellular Cys (cysteine)(122)-to-Cys(154) disulfide bond in the channel structure is crucial for proper folding but has not been associated with correct channel function at the membrane. We evaluated whether a human mutation at the Cys(122)-to-Cys(154) disulfide bridge leads to Kir2.1 channel dysfunction and arrhythmias by reorganizing the overall Kir2.1 channel structure and destabilizing its open state. METHODS: We identified a Kir2.1 loss-of-function mutation (c.366 A>T; p.Cys122Tyr) in an ATS1 family. To investigate its pathophysiological implications, we generated an AAV9-mediated cardiac-specific mouse model expressing the Kir2.1(C122Y) variant. We employed a multidisciplinary approach, integrating patch clamping and intracardiac stimulation, molecular biology techniques, molecular dynamics, and bioluminescence resonance energy transfer experiments. RESULTS: Kir2.1(C122Y) mice recapitulated the ECG features of ATS1 independently of sex, including corrected QT prolongation, conduction defects, and increased arrhythmia susceptibility. Isolated Kir2.1(C122Y) cardiomyocytes showed significantly reduced inwardly rectifier K+ (I-K1) and inward Na+ (I-Na) current densities independently of normal trafficking. Molecular dynamics predicted that the C122Y mutation provoked a conformational change over the 2000-ns simulation, characterized by a greater loss of hydrogen bonds between Kir2.1 and phosphatidylinositol 4,5-bisphosphate than wild type (WT). Therefore, the phosphatidylinositol 4,5-bisphosphate-binding pocket was destabilized, resulting in a lower conductance state compared with WT. Accordingly, on inside-out patch clamping, the C122Y mutation significantly blunted Kir2.1 sensitivity to increasing phosphatidylinositol 4,5-bisphosphate concentrations. In addition, the Kir2.1(C122Y) mutation resulted in channelosome degradation, demonstrating temporal instability of both Kir2.1 and Na(V)1.5 proteins. CONCLUSIONS: The extracellular Cys(122)-to-Cys(154) disulfide bond in the tridimensional Kir2.1 channel structure is essential for the channel function. We demonstrate that breaking disulfide bonds in the extracellular domain disrupts phosphatidylinositol 4,5-bisphosphate-dependent regulation, leading to channel dysfunction and defects in Kir2.1 energetic stability. The mutation also alters functional expression of the Na(V)1.5 channel and ultimately leads to conduction disturbances and life-threatening arrhythmia characteristic of Andersen-Tawil syndrome type 1.

9 June 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
FCFrancisco Miguel Cruz
Francisco Miguel Cruz
Álvaro MacíasÁlvaro Macías
Álvaro Macías
AMAna I I. Moreno-Manuel
Ana I I. Moreno-Manuel
LGLilian K. Gutiérrez
Lilian K. Gutiérrez
MVMaría Linarejos Vera-Pedrosa
María Linarejos Vera-Pedrosa
Jose JalifeJose Jalife
Jose Jalife
Background: Andersen-Tawil Syndrome Type 1 (ATS1) is a rare heritable disease caused by mutations in the strong inwardly rectifying K + channel Kir2.1. The extracellular Cys122-to-Cys154 disulfide bond in the Kir2.1 channel structure is crucial for proper folding, but has not been associated with correct channel function at the membrane. We tested whether a human mutation at the Cys122-to-Cys154 disulfide bridge leads to Kir2.1 channel dysfunction and arrhythmias by reorganizing the overall Kir2.1 channel structure and destabilizing the open state of the channel. Methods and Results: We identified a Kir2.1 loss-of-function mutation in Cys122 (c.366 A>T; p.Cys122Tyr) in a family with ATS1. To study the consequences of this mutation on Kir2.1 function we generated a cardiac specific mouse model expressing the Kir2.1 C122Y mutation. Kir2.1 C122Y animals recapitulated the abnormal ECG features of ATS1, like QT prolongation, conduction defects, and increased arrhythmia susceptibility. Kir2.1 C122Y mouse cardiomyocytes showed significantly reduced inward rectifier K + (I K1 ) and inward Na + (I Na ) current densities independently of normal trafficking ability and localization at the sarcolemma and the sarcoplasmic reticulum. Kir2.1 C122Y formed heterotetramers with wildtype (WT) subunits. However, molecular dynamic modeling predicted that the Cys122-to-Cys154 disulfide-bond break induced by the C122Y mutation provoked a conformational change over the 2000 ns simulation, characterized by larger loss of the hydrogen bonds between Kir2.1 and phosphatidylinositol-4,5-bisphosphate (PIP 2 ) than WT. Therefore, consistent with the inability of Kir2.1 C 122 Y channels to bind directly to PIP 2 in bioluminescence resonance energy transfer experiments, the PIP 2 binding pocket was destabilized, resulting in a lower conductance state compared with WT. Accordingly, on inside-out patch-clamping the C122Y mutation significantly blunted Kir2.1 sensitivity to increasing PIP 2 concentrations. Conclusion: The extracellular Cys122-to-Cys154 disulfide bond in the tridimensional Kir2.1 channel structure is essential to channel function. We demonstrated that ATS1 mutations that break disulfide bonds in the extracellular domain disrupt PIP 2 -dependent regulation, leading to channel dysfunction and life-threatening arrhythmias. CLINICAL PERSPECTIVE: NOVELTY AND SIGNIFICANCE: What is known? Andersen-Tawil Syndrome Type 1 (ATS1) is a rare arrhythmogenic disease caused by loss-of-function mutations in KCNJ2 , the gene encoding the strong inward rectifier potassium channel Kir2.1 responsible for I K1 . Extracellular Cys 122 and Cys 154 form an intramolecular disulfide bond that is essential for proper Kir2.1 channel folding but not considered vital for channel function. Replacement of Cys 122 or Cys 154 residues in the Kir2.1 channel with either alanine or serine abolished ionic current in Xenopus laevis oocytes. What new information does this article contribute? We generated a mouse model that recapitulates the main cardiac electrical abnormalities of ATS1 patients carrying the C122Y mutation, including prolonged QT interval and life-threatening ventricular arrhythmias. We demonstrate for the first time that a single residue mutation causing a break in the extracellular Cys122-to-Cys154 disulfide-bond leads to Kir2.1 channel dysfunction and arrhythmias in part by reorganizing the overall Kir2.1 channel structure, disrupting PIP2-dependent Kir2.1 channel function and destabilizing the open state of the channel. Defects in Kir2.1 energetic stability alter the functional expression of the voltage-gated cardiac sodium channel Nav1.5, one of the main Kir2.1 interactors in the macromolecular channelosome complex, contributing to the arrhythmias. The data support the idea that susceptibility to arrhythmias and SCD in ATS1 are specific to the type and location of the mutation, so that clinical management should be different for each patient. Altogether, the results may lead to the identification of new molecular targets in the future design of drugs to treat a human disease that currently has no defined therapy.

11 December 2024 in medRxiv
Verified
Preprint
Open access
PDF file
FCFrancisco M. Cruz
Francisco M. Cruz
AMAna I. Moreno-Manuel
Ana I. Moreno-Manuel
SPSánchez Pérez Patricia
Sánchez Pérez Patricia
JRJuan Manuel Ruiz-Robles
Juan Manuel Ruiz-Robles
PSPaula G Socuéllamos
Paula G Socuéllamos
Jose JalifeJose Jalife
Jose Jalife
Background: Flecainide and other class-Ic antiarrhythmic drugs (AADs) are widely used in Andersen-Tawil syndrome type 1 (ATS1) patients. However, class-Ic drugs might be proarrhythmic in some cases. We investigated the molecular mechanisms of class-I AADs proarrhythmia and whether they might increase the risk of death in ATS1 patients with structurally normal hearts. Methods and Results: Of 53 ATS1 patients reviewed from the literature, 54% responded partially to flecainide, with ventricular arrhythmia (VA) reduction in only 23%. Of the latter patients, VA persisted in 20-50%. Flecainide was ineffective in 23%, and surprisingly, 13.5% suffered a non-fatal cardiac arrest. In five cardiac-specific ATS1 mouse models (Kir2.1 Δ314–315 , Kir2.1 C122Y , Kir2.1 G215D and Kir2.1 R67W and Kir2.1 S136F ), flecainide or propafenone (40 mg/Kg i.p.) differentially prolonged the P wave, and the PR, QRS and QTc intervals compared to Kir2.1 WT ; Kir2.1 S136F had milder effects. Flecainide increased VA inducibility in all mutant mice except Kir2.1 S136F , which exhibited significant VA reduction. At baseline, Kir2.1 G215D cardiomyocytes had the lowest inward rectifier K+ channel (I K1 ) reduction, followed by Kir2.1 C122Y , Kir2.1 R67W and Kir2.1 S136F . Kir2.1 C122Y cardiomyocytes had a significant decrease in sodium inward current (I Na ). Flecainide (10 µM) slightly increased I K1 density in Kir2.1 WT and Kir2.1 S136F , while it decreased both I K1 and I Na in Kir2.1 C122Y and Kir2.1 R67W , despite normal trafficking of mutant channels. Optical mapping in ATS1 patient-specific iPSC-CM monolayers expressing Kir2.1 C122Y , Kir2.1 G215D and Kir2.1 R67W showed an increase in rotor incidence at baseline and under flecainide, confirming the druǵs proarrhythmic effect. Lastly, in-silico molecular docking predicts that the Kir2.1-Cys 311 pharmacophore-binding site is altered in Kir2.1 C122Y heterotetramers, reducing flecainide accessibility and leading to channel closure and arrhythmias. Conclusions: Class-Ic AADs are only partially effective and might be proarrhythmic in some ATS1 patients. Kir2.1 mutations impacting the resting membrane potential and cellular excitability create a substrate for life-threatening arrhythmias, raising significant concern about using these drugs in some ATS1 patients. CLINICAL PERSPECTIVE NOVELTY AND SIGNIFICANCE: What is known?: Andersen-Tawil syndrome type 1 (ATS1) is a rare autosomal dominant disease caused by loss-of-function mutations in the KCNJ2 gene, which encodes the Kir2.1 channel responsible for the repolarizing, strong inwardly rectifying current I K1 . ATS1 treatment is empirical and subject to clinical judgment. It includes the use of class-Ic antiarrhythmic drugs (AADs), mainly flecainide, alone or in combination with β-adrenergic blocking drugs. However, pharmacological treatment is partial and might fail, leading to life-threatening ventricular arrhythmias (VA) and sudden cardiac death (SCD) in some ATS1 patients. Some ATS1 mutations are known to disrupt the Kir2.1-Nav1.5 channelosome in mice and human iPSC-CMs, with consequent reductions in cardiac excitability and conduction velocity (CV), leading to VA, which may be exacerbated by flecainide. What new information does this article contribute?: In our analysis of 53 ATS1 patients, flecainide showed partial effectiveness. While a few patients experienced complete disappearance of VA, others had persistent arrhythmias and even suffered non-fatal cardiac arrest while on medication. In murine models expressing five relevant ATS1 mutations, flecainide or propafenone produced differential alteration in the P wave, PR, QRS and QTc intervals, and increased VA inducibility compared with Kir2.1 WT mice. Additionally, flecainide differentially affected I K1 and the Na + inward current (I Na ) current densities despite normal trafficking of mutant channels. In patient-specific induced pluripotent stem cell derived cardiomyocyte (iPSC-CM) monolayers flecainide reduced CV and increased rotor incidence, confirming the drugś proarrhythmic effect. In-silico molecular docking studies predicted that the Cys 311 pharmacophore binding site and flecainide accessibility are altered in mutated Kir2.1 channels, leading to premature channel closure and arrhythmias. We conclude that class-Ic AADs are only partially effective and might be proarrhythmic in some ATS1 patients. These findings raise concern about the use of class-Ic AADs in ATS1 patients and highlight the need for further studies to guide personalized therapy.

10 November 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
JRJuan Manuel Ruiz-Robles
Juan Manuel Ruiz-Robles
IMIsabel Martínez-Carrascoso
Isabel Martínez-Carrascoso
ÁMÁlvaro Macías
Álvaro Macías
AMAna I. Moreno-Manuel
Ana I. Moreno-Manuel
PSPatricia Sánchez-Pérez
Patricia Sánchez-Pérez
FCFrancisco M. Cruz
Francisco M. Cruz
Short QT Syndrome (SQTS) is a rare cardiac channelopathy characterized by abnormally short QTc intervals and increased sudden cardiac death (SCD) risk. Only 20-30% of SQTS cases have been linked to genetic mutations, typically in surface membrane ion channels. We identified a novel lysosomal TMEM175 gene mutation (p.Arg377His) in 7 patients in a family with SQTS and SCD. Genetic analyses, including whole exome sequencing in the family and rare-variant burden testing in ∼118,000 UK Biobank participants, suggested an association between TMEM175 rare variants and QT interval shortening. Functional studies in CRISPR-engineered mice and patient-specific induced pluripotent stem cellderived cardiomyocytes (iPSC-CMs) revealed that TMEM175 R377H causes shortened QT intervals and hastened repolarization, respectively, as well an increased arrhythmia susceptibility. Isolated TMEM175 R377H cardiomyocytes showed action potential duration (APD) abbreviation, confirmed in whole TMEM175 R377H mouse hearts and patient-specific iPSC-CM monolayers. In silico and electron microscopy studies showed that TMEM175 R377H disrupts lysosomal-mitochondrial interactions, leading to mitochondrial dysfunction, as evidenced by the reduced maximal respiration and spare respiratory capacity, with reduced ATP production, I KATP activation, and APD shortening. This mutation represents the first non-sarcolemmal ion channel defect associated with SQTS and high SCD risk, potentially expanding the genetic landscape of the disease.